Drug intelligence / Profile preview

Yunnan Univ. of Chinese Medicine CYP51 compound 4s

Development stage: Unknown
Lead developer: Yunnan University of Chinese Medicine

Overview

Yunnan Univ. of Chinese Medicine CYP51 compound 4s: sourced facts only. name: "Therefore, 4s could be considered as a new antifungal agent targeting CYP51 for further study." [PMID:39539346]; target: "Therefore, 4s could be considered as a new antifungal agent targeting CYP51 for further study." [PMID:39539346]; developer: "School of Chinese Materia Medica, Yunnan University of Chinese Medicine Kunming 650500 PR China [email protected] [email protected] [email protected]." [PMID:39539346]

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on Yunnan Univ. of Chinese Medicine CYP51 compound 4s.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yunnan Univ. of Chinese Medicine CYP51 compound 4s.